Cargando…
Tolerability of concurrent external beam radiotherapy and [(177)Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial)
BACKGROUND: Prostate cancer patients with locoregional lymph node disease at diagnosis (N1M0) still have a limited prognosis despite the improvements provided by aggressive curative intent multimodal locoregional external beam radiation therapy (EBRT) with systemic androgen deprivation therapy (ADT)...
Autores principales: | van der Sar, Esmée C. A., Braat, Arthur J. A. T., van der Voort- van Zyp, Jochem R. N., van der Veen, Betty S., van Leeuwen, Pim J., de Vries-Huizing, Daphne M. V., Hendrikx, Jeroen M. A., Lam, Marnix G. E. H., Vogel, Wouter V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035228/ https://www.ncbi.nlm.nih.gov/pubmed/36959540 http://dx.doi.org/10.1186/s12885-023-10725-5 |
Ejemplares similares
-
Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023) -
Baseline Imaging Derived Predictive Factors of Response Following [(177)Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis
por: van der Sar, Esmée C. A., et al.
Publicado: (2022) -
Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022) -
Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023) -
Improved quality control of [(177)Lu]Lu-PSMA I&T
por: Kraihammer, Martin, et al.
Publicado: (2023)